307 Shares in Agilent Technologies, Inc. (NYSE:A) Acquired by Arlington Trust Co LLC

Arlington Trust Co LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A) in the 4th quarter, Holdings Channel reports. The firm acquired 307 shares of the medical research company’s stock, valued at approximately $43,000.

Other hedge funds also recently added to or reduced their stakes in the company. Kepos Capital LP lifted its stake in Agilent Technologies by 3.5% during the third quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock worth $310,000 after purchasing an additional 93 shares in the last quarter. Ancora Advisors LLC lifted its stake in Agilent Technologies by 41.1% during the first quarter. Ancora Advisors LLC now owns 326 shares of the medical research company’s stock worth $45,000 after purchasing an additional 95 shares in the last quarter. Rosenberg Matthew Hamilton lifted its stake in Agilent Technologies by 51.1% during the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares in the last quarter. Ronald Blue Trust Inc. lifted its stake in Agilent Technologies by 8.1% during the third quarter. Ronald Blue Trust Inc. now owns 1,336 shares of the medical research company’s stock worth $161,000 after purchasing an additional 100 shares in the last quarter. Finally, Invesco LLC raised its stake in shares of Agilent Technologies by 0.7% in the third quarter. Invesco LLC now owns 15,471 shares of the medical research company’s stock valued at $1,730,000 after acquiring an additional 101 shares in the last quarter. 87.42% of the stock is currently owned by hedge funds and other institutional investors.

Agilent Technologies Stock Performance

Shares of A stock opened at $144.12 on Monday. The stock’s 50-day moving average is $139.85 and its two-hundred day moving average is $127.89. The firm has a market cap of $42.24 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 4.36 and a beta of 1.11. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $151.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.04 and a current ratio of 2.68.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter last year, the company posted $1.37 earnings per share. The business’s revenue was down 5.5% on a year-over-year basis. Analysts predict that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the sale, the vice president now directly owns 21,329 shares in the company, valued at approximately $3,178,021. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,610 shares of company stock valued at $9,220,333. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A has been the topic of several analyst reports. Barclays increased their price objective on Agilent Technologies from $120.00 to $125.00 and gave the company an “underweight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. increased their price objective on Agilent Technologies from $140.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Wolfe Research started coverage on Agilent Technologies in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $140.00 price target on the stock. Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and raised their price target for the company from $145.00 to $163.00 in a research note on Friday. Finally, Oppenheimer raised their price target on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $140.71.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.